Get the Stockscreener App
6.79
3.96%
-0.28
After Hours:
6.70
-0.09
-1.33%
Maravai Lifesciences Holdings Inc stock is traded at $6.79, with a volume of 2.22M.
It is down -3.96% in the last 24 hours and down -0.73% over the past month.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
See More
Previous Close:
$7.07
Open:
$7.05
24h Volume:
2.22M
Relative Volume:
0.76
Market Cap:
$1.01B
Revenue:
$204.73M
Net Income/Loss:
$-184.29M
P/E Ratio:
-9.3966
EPS:
-0.7226
Net Cash Flow:
$-51.87M
1W Performance:
-8.74%
1M Performance:
-0.73%
6M Performance:
+99.12%
1Y Performance:
+94.56%
1-Day Range:
$6.735
$7.08
1-Week Range:
$6.334
$7.381
52-Week Range:
$2.545
$9.42
Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile
Name
Maravai Lifesciences Holdings Inc
Sector
Industry
Phone
(858) 546-0004
Address
10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO
Compare MRVI vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRVI
Maravai Lifesciences Holdings Inc
|
6.79 | 1.01B | 204.73M | -184.29M | -51.87M | -0.7226 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-05-26 | Initiated | TD Cowen | Buy |
| Feb-26-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-19-24 | Initiated | Guggenheim | Neutral |
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Nov-14-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-08-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Aug-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-10-24 | Initiated | Craig Hallum | Buy |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-08-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| May-23-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-09-23 | Downgrade | Goldman | Buy → Neutral |
| Jan-05-23 | Downgrade | UBS | Buy → Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-22 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Dec-15-20 | Initiated | BofA Securities | Buy |
| Dec-15-20 | Initiated | Credit Suisse | Outperform |
| Dec-15-20 | Initiated | Goldman | Buy |
| Dec-15-20 | Initiated | Jefferies | Buy |
| Dec-15-20 | Initiated | Robert W. Baird | Outperform |
| Dec-15-20 | Initiated | Stifel | Buy |
| Dec-15-20 | Initiated | William Blair | Outperform |
| Dec-14-20 | Initiated | UBS | Buy |
View All
Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News
Syndax's Revuforj named one of TIME's Best Inve... - Pluang
Millennium Management Reports 5.2% Stake in Maravai LifeSciences Holdings - kalkinemedia.com
More than 5% of Maravai LifeSciences (MRVI) shares are listed with shared voting power. - Stock Titan
Maravai LifeSciences Holdings, Inc.Class A common stock (NQ: MRVI - The Chronicle-Journal
Maravai Lifesciences CEO Brust Bernd Forfeits 29,250 Shares at $7.32 Each (NASDAQ: MRVI) - Kalkine Media
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com South Africa
MRVI Maintained by UBS -- Price Target Raised to $8.00 - GuruFocus
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com Nigeria
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com Canada
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com India
UBS reiterates Maravai LifeSciences stock Neutral rating at $8 target By Investing.com - Investing.com UK
Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel (MRVI) - Seeking Alpha
Maravai (NASDAQ: MRVI) CFO now holds 423K shares after tax withholding - stocktitan.net
Maravai (MRVI) Technicals: Ends Up by 4.22% at $8.64 in Latest Trading - vinanet.vn
12 Health Care Stocks Moving In Thursday's Intraday Session - Sahm
Why Maravai LifeSciences Holdings (MRVI) Stock Climbed After Its Latest Update - Sahm
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Maravai Lifesciences stock reaches 52-week high of 8.15 USD By Investing.com - Investing.com Nigeria
Maravai Lifesciences stock reaches 52-week high of 8.15 USD By Investing.com - Investing.com India
Maravai Lifesciences stock reaches 52-week high of 8.15 USD - investing.com
Maravai (MRVI) Earnings Reading: EPS Prints Above Forecast in the Latest Reading; Closing Move: The Market Price Advances 25.78% in Latest TradingPost-Announcement Reaction - vinanet.vn
Maravai Lifesciences Up Over 30%, on Pace for Largest Percent Increase in Over a Year -- Data Talk - Bitget
MRVI Q2 2026 Earnings: Narrower-Than-Expected Loss Points to Cost DisciplineNew Analyst Coverage - vinanet.vn
Maravai Lifesciences Earnings Call Highlights Margin Rebound - TipRanks
MRVI Q2 2026 Earnings: Loss Narrows Sharply as EPS Beats Estimates by 54.65%Post-Announcement Reaction - vinanet.vn
Maravai LifeSciences (MRVI) Slides 1.38% to $5.70 as Key Support Level Comes into FocusALMA Signal - vinanet.vn
Wall Street Zen Upgrades Maravai LifeSciences (NASDAQ:MRVI) to Buy - MarketBeat
Maravai (MRVI) Q2 2026 Earnings Call Transcript - AOL.com
Maravai LifeSciences (MRVI) group reports 4.0M shares, 2.72% beneficial stake - Stock Titan
Dimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVI - MarketBeat
Maravai (MRVI) Q2 2026 Earnings Call Transcript - The Globe and Mail
Maravai LifeSciences (NASDAQ:MRVI) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Maravai Q2 2026 slides: margin expansion drives EBITDA guidance raise By Investing.com - Investing.com Nigeria
Maravai LifeSciences (MRVI) Releases Q2 2026 Earnings: Revenue Beats Estimates and Loss Narrows - Quiver Quantitative
Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating - Moomoo
Maravai LifeSciences Holdings, Inc. (MRVI) stock price, news, quote and history - Yahoo Finance Singapore
MRVI Maintains Overweight Rating by Wells Fargo -- Price Target Raised to $6.50 - GuruFocus
Maravai LifeSciences (NASDAQ:MRVI) Shares Gap DownHere's What Happened - MarketBeat
Wells Fargo & Company Issues Positive Forecast for Maravai LifeSciences (NASDAQ:MRVI) Stock Price - MarketBeat
Maravai LifeSciences posts investor presentation on mRNA, gene editing, cell and gene therapy tools platform - Bitget
Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating - marketscreener.com
Deutsche Bank Adjusts Maravai Lifesciences PT to $8 From $6, Maintains Buy Rating - Yahoo Finance
Earnings call transcript: Maravai LifeSciences beats Q2 2026 estimates, shares fall - Investing.com South Africa
Maravai LifeSciences Holdings (MRVI) Stock Analysis: Navigating Challenges with Biotech Innovation - DirectorsTalk Interviews
MRVI Looks 63.2% Overvalued on GF Value™ - GuruFocus
Is Maravai LifeSciences (MRVI) Overvalued After Q2 Earnings Miss? GF Score: 61/100 - GuruFocus
Maravai LifeSciences Q2 Earnings Call Highlights - Yahoo Finance
Maravai LifeSciences Q2 Earnings Call Highlights - TradingView
Maravai LifeSciences Holdings Inc (MRVI) (Q2 2026) Earnings Call - GuruFocus
Levi & Korsinsky Notifies Maravai LifeSciences Holdings, Inc. Inv - The National Law Review
Maravai Lifesciences Holdings Inc Stock (MRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maravai Lifesciences Holdings Inc Stock (MRVI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORESHACK KURT | Officer |
Jun 10 '26 |
Proposed Sale |
5.10 |
25,000 |
127,500 |
0 |
| ORESHACK KURT | General Counsel |
Jun 09 '26 |
Sale |
5.06 |
25,000 |
126,500 |
360,767 |
| ORESHACK KURT | Officer |
Jun 09 '26 |
Proposed Sale |
5.06 |
25,000 |
126,500 |
0 |
| PRAHALAD MURALI | Former Director |
Dec 23 '25 |
Proposed Sale |
3.33 |
3,951 |
13,138 |
0 |
| Hopfield Jessica | Former Director |
Dec 19 '25 |
Proposed Sale |
3.48 |
53,951 |
187,526 |
0 |
| LUCIER GREGORY T | Director |
Dec 08 '25 |
Buy |
3.67 |
48,528 |
178,098 |
155,123 |
| LUCIER GREGORY T | Director |
Dec 05 '25 |
Buy |
3.70 |
51,472 |
190,446 |
106,595 |
| Brust Bernd | Chief Executive Officer |
Nov 13 '25 |
Buy |
3.25 |
216,212 |
702,689 |
466,771 |
| Brust Bernd | Chief Executive Officer |
Nov 12 '25 |
Buy |
3.21 |
93,358 |
299,679 |
250,559 |
| Brust Bernd | Chief Executive Officer |
Nov 11 '25 |
Buy |
3.24 |
157,201 |
509,331 |
157,201 |
4.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):